Calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia
Full results from the Phase III ELEVATE TN trial showed 93% of patients on Calquence combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24 months Trial also showed 87% of patients on Calquence alone remained free of disease progression or death at 24 monthsAstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that Calquence (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS) compared to